Beta Bionics (NASDAQ:BBNX) Coverage Initiated at Leerink Partners

Equities research analysts at Leerink Partners began coverage on shares of Beta Bionics (NASDAQ:BBNX - Get Free Report) in a research report issued on Monday, MarketBeat reports. The firm set an "outperform" rating and a $28.00 price target on the stock. Leerink Partners' price objective suggests a potential upside of 40.63% from the company's current price.

BBNX has been the topic of a number of other research reports. Baird R W upgraded Beta Bionics to a "hold" rating in a report on Thursday, February 20th. Robert W. Baird initiated coverage on Beta Bionics in a research note on Thursday, February 20th. They set a "neutral" rating and a $20.00 price objective on the stock. Finally, LADENBURG THALM/SH SH started coverage on shares of Beta Bionics in a research note on Thursday, February 20th. They issued a "neutral" rating and a $20.00 target price for the company. Three research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Beta Bionics currently has an average rating of "Moderate Buy" and an average target price of $24.83.

Beta Bionics Price Performance

Shares of NASDAQ:BBNX traded down $0.08 during midday trading on Monday, hitting $19.91. 389,619 shares of the company's stock were exchanged, compared to its average volume of 332,212. Beta Bionics has a 12 month low of $18.67 and a 12 month high of $24.50.

Remove Ads

Insider Buying and Selling

In other news, insider Mike Mensinger purchased 33,350 shares of the business's stock in a transaction dated Friday, January 31st. The stock was bought at an average price of $17.00 per share, for a total transaction of $566,950.00. Following the purchase, the insider now owns 59,019 shares of the company's stock, valued at $1,003,323. The trade was a 129.92 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Hadley Harbor Aggre Wellington bought 1,000,000 shares of the business's stock in a transaction on Friday, January 31st. The shares were acquired at an average price of $17.00 per share, with a total value of $17,000,000.00. Following the transaction, the insider now directly owns 3,901,599 shares of the company's stock, valued at approximately $66,327,183. This trade represents a 34.46 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

About Beta Bionics

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.